Rights Offer to fund early return to clinic and growth
Filed with ASX · · 4 pages · English
Earlier from AdAlta
- Publication highlights I-body potential in osteoporosis
- AdAlta welcomes new substantial shareholders
- Second Japan patent for AD-214
- AD-214 progress and priorities webinar presentation
- AD-214 progress and priorities
Later from AdAlta
- AdAlta to support early return to clinical trials of AD-214 with rights offer
- Rights Offer results
- AdAlta secures A$1.28 million in rights offer to advance AD-214
- AdAlta to present at June 1 Virtual Investor Summit
- AD-214 clinical trial approval
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta